| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory Tract Infections | 13 | 2018 | 437 | 2.530 |
Why?
|
| Respiratory Syncytial Virus Infections | 14 | 2021 | 427 | 2.170 |
Why?
|
| Antiviral Agents | 19 | 2020 | 1230 | 1.570 |
Why?
|
| Ribavirin | 8 | 2018 | 178 | 1.380 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 23 | 2021 | 6550 | 1.310 |
Why?
|
| Paramyxoviridae Infections | 4 | 2017 | 86 | 1.230 |
Why?
|
| Respiratory Syncytial Virus, Human | 7 | 2021 | 211 | 1.110 |
Why?
|
| Aerosols | 4 | 2013 | 158 | 1.090 |
Why?
|
| Hematologic Neoplasms | 8 | 2018 | 1870 | 1.030 |
Why?
|
| Influenza, Human | 6 | 2017 | 925 | 0.860 |
Why?
|
| Transplant Recipients | 7 | 2021 | 324 | 0.790 |
Why?
|
| Hepatitis B Vaccines | 4 | 2015 | 51 | 0.770 |
Why?
|
| Neoplasms | 22 | 2023 | 15193 | 0.750 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 355 | 0.710 |
Why?
|
| Cytomegalovirus Infections | 6 | 2020 | 462 | 0.700 |
Why?
|
| Feces | 2 | 2021 | 770 | 0.650 |
Why?
|
| Hepatitis B | 4 | 2015 | 258 | 0.630 |
Why?
|
| Bacteria | 2 | 2021 | 611 | 0.610 |
Why?
|
| Metapneumovirus | 2 | 2017 | 58 | 0.580 |
Why?
|
| Drug Users | 2 | 2015 | 18 | 0.560 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 715 | 0.540 |
Why?
|
| Immunization Schedule | 2 | 2015 | 117 | 0.540 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2015 | 238 | 0.520 |
Why?
|
| Hepacivirus | 2 | 2012 | 397 | 0.430 |
Why?
|
| Respiratory Syncytial Viruses | 3 | 2019 | 171 | 0.420 |
Why?
|
| Energy Metabolism | 1 | 2018 | 992 | 0.420 |
Why?
|
| Viral Load | 3 | 2019 | 493 | 0.420 |
Why?
|
| Occupational Exposure | 2 | 2014 | 244 | 0.400 |
Why?
|
| Antibodies, Viral | 6 | 2021 | 1320 | 0.400 |
Why?
|
| Middle Aged | 36 | 2023 | 86204 | 0.380 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2021 | 907 | 0.380 |
Why?
|
| Transplantation Conditioning | 2 | 2018 | 2238 | 0.370 |
Why?
|
| Pandemics | 4 | 2022 | 1559 | 0.370 |
Why?
|
| Cohort Studies | 11 | 2023 | 9244 | 0.360 |
Why?
|
| Viral Fusion Proteins | 3 | 2020 | 85 | 0.360 |
Why?
|
| Aged | 33 | 2023 | 70117 | 0.360 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 242 | 0.360 |
Why?
|
| Accidents, Occupational | 1 | 2009 | 12 | 0.350 |
Why?
|
| Cytomegalovirus | 5 | 2020 | 482 | 0.350 |
Why?
|
| Hand Injuries | 1 | 2009 | 18 | 0.340 |
Why?
|
| Agriculture | 1 | 2009 | 37 | 0.340 |
Why?
|
| Transients and Migrants | 1 | 2009 | 27 | 0.340 |
Why?
|
| Male | 42 | 2023 | 123000 | 0.330 |
Why?
|
| Drug Resistance, Viral | 3 | 2016 | 71 | 0.320 |
Why?
|
| Venous Thromboembolism | 2 | 2023 | 335 | 0.310 |
Why?
|
| Enzyme-Linked Immunospot Assay | 2 | 2019 | 33 | 0.310 |
Why?
|
| Lung | 1 | 2018 | 3151 | 0.300 |
Why?
|
| Female | 40 | 2023 | 141928 | 0.300 |
Why?
|
| Humans | 59 | 2023 | 261506 | 0.300 |
Why?
|
| Host-Pathogen Interactions | 2 | 2021 | 314 | 0.300 |
Why?
|
| Incidence | 6 | 2019 | 5673 | 0.290 |
Why?
|
| Hepatitis C, Chronic | 1 | 2012 | 451 | 0.290 |
Why?
|
| Young Adult | 14 | 2018 | 21445 | 0.280 |
Why?
|
| Immunocompromised Host | 4 | 2018 | 698 | 0.260 |
Why?
|
| Risk Factors | 12 | 2022 | 17523 | 0.250 |
Why?
|
| Prostatic Neoplasms | 2 | 2019 | 5767 | 0.250 |
Why?
|
| Adult | 24 | 2023 | 77950 | 0.240 |
Why?
|
| Adolescent | 15 | 2023 | 31252 | 0.240 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 598 | 0.240 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2021 | 490 | 0.230 |
Why?
|
| Retrospective Studies | 18 | 2023 | 37905 | 0.230 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2015 | 1209 | 0.220 |
Why?
|
| Antibodies, Neutralizing | 4 | 2021 | 541 | 0.220 |
Why?
|
| Cross Infection | 3 | 2017 | 544 | 0.220 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 651 | 0.210 |
Why?
|
| Rural Population | 2 | 2022 | 281 | 0.210 |
Why?
|
| Seroconversion | 1 | 2021 | 19 | 0.200 |
Why?
|
| Lymphatic Diseases | 1 | 2022 | 128 | 0.200 |
Why?
|
| Viral Structural Proteins | 1 | 2021 | 47 | 0.200 |
Why?
|
| Gloves, Surgical | 1 | 2021 | 10 | 0.200 |
Why?
|
| Child, Preschool | 8 | 2017 | 16273 | 0.200 |
Why?
|
| Antigens, Viral | 2 | 2020 | 471 | 0.190 |
Why?
|
| Immunity, Mucosal | 1 | 2021 | 108 | 0.190 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 86 | 0.190 |
Why?
|
| Palivizumab | 2 | 2018 | 64 | 0.190 |
Why?
|
| Liver Diseases | 2 | 2019 | 574 | 0.190 |
Why?
|
| Urban Population | 1 | 2022 | 269 | 0.190 |
Why?
|
| Vaccination | 3 | 2016 | 1123 | 0.190 |
Why?
|
| Influenza Vaccines | 2 | 2016 | 635 | 0.180 |
Why?
|
| Health Personnel | 2 | 2016 | 625 | 0.180 |
Why?
|
| Stomatitis | 1 | 2020 | 183 | 0.170 |
Why?
|
| Drug Utilization | 1 | 2020 | 179 | 0.170 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 15694 | 0.170 |
Why?
|
| Immunity | 1 | 2021 | 342 | 0.170 |
Why?
|
| Specimen Handling | 1 | 2021 | 299 | 0.170 |
Why?
|
| Texas | 4 | 2015 | 6311 | 0.160 |
Why?
|
| Rubulavirus | 1 | 2018 | 8 | 0.160 |
Why?
|
| Respiratory Mucosa | 1 | 2020 | 206 | 0.160 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 207 | 0.160 |
Why?
|
| Rectum | 1 | 2021 | 467 | 0.160 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 4892 | 0.160 |
Why?
|
| Virus Activation | 2 | 2019 | 228 | 0.160 |
Why?
|
| Leukopenia | 1 | 2018 | 151 | 0.160 |
Why?
|
| Ribotyping | 1 | 2018 | 48 | 0.160 |
Why?
|
| Administration, Inhalation | 3 | 2014 | 285 | 0.160 |
Why?
|
| Substance-Related Disorders | 2 | 2014 | 524 | 0.160 |
Why?
|
| United States | 5 | 2023 | 15433 | 0.160 |
Why?
|
| Hypoxia | 2 | 2017 | 443 | 0.150 |
Why?
|
| Child | 8 | 2017 | 29154 | 0.150 |
Why?
|
| Odds Ratio | 4 | 2022 | 2316 | 0.150 |
Why?
|
| Mexico | 1 | 2017 | 259 | 0.150 |
Why?
|
| Serum Albumin | 1 | 2017 | 257 | 0.150 |
Why?
|
| Organophosphonates | 1 | 2016 | 64 | 0.140 |
Why?
|
| Isoxazoles | 1 | 2016 | 81 | 0.140 |
Why?
|
| Prospective Studies | 6 | 2023 | 12873 | 0.140 |
Why?
|
| Logistic Models | 3 | 2019 | 3441 | 0.140 |
Why?
|
| Lymphocyte Transfusion | 1 | 2016 | 175 | 0.140 |
Why?
|
| Cytosine | 1 | 2016 | 141 | 0.130 |
Why?
|
| Coinfection | 1 | 2017 | 189 | 0.130 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 180 | 0.130 |
Why?
|
| Herpesviridae Infections | 1 | 2016 | 175 | 0.130 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2015 | 152 | 0.130 |
Why?
|
| Herbaspirillum | 1 | 2014 | 6 | 0.130 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2019 | 661 | 0.130 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2016 | 87 | 0.130 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 260 | 0.130 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 29902 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2017 | 285 | 0.120 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 1363 | 0.120 |
Why?
|
| Microbiota | 1 | 2020 | 547 | 0.120 |
Why?
|
| Blood | 1 | 2014 | 156 | 0.120 |
Why?
|
| Central Venous Catheters | 1 | 2014 | 98 | 0.110 |
Why?
|
| Genotype | 3 | 2016 | 4109 | 0.110 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2014 | 158 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 3719 | 0.110 |
Why?
|
| Transplantation | 1 | 2013 | 56 | 0.110 |
Why?
|
| Infant | 4 | 2017 | 13310 | 0.110 |
Why?
|
| Treatment Outcome | 7 | 2020 | 32848 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2019 | 2450 | 0.110 |
Why?
|
| Cause of Death | 3 | 2022 | 752 | 0.110 |
Why?
|
| Hepatitis C Antibodies | 1 | 2012 | 41 | 0.100 |
Why?
|
| Behavior | 1 | 2012 | 103 | 0.100 |
Why?
|
| Catheter-Related Infections | 1 | 2014 | 270 | 0.100 |
Why?
|
| Survival Analysis | 2 | 2013 | 9180 | 0.100 |
Why?
|
| Virus Diseases | 1 | 2014 | 398 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2018 | 6100 | 0.090 |
Why?
|
| Demography | 1 | 2012 | 435 | 0.090 |
Why?
|
| Hydroxychloroquine | 2 | 2020 | 32 | 0.090 |
Why?
|
| Immunologic Memory | 1 | 2012 | 374 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 573 | 0.090 |
Why?
|
| Regression Analysis | 2 | 2014 | 1546 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 1303 | 0.090 |
Why?
|
| Comorbidity | 3 | 2021 | 2352 | 0.090 |
Why?
|
| Vaccines | 1 | 2014 | 389 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2012 | 671 | 0.090 |
Why?
|
| Virus Shedding | 2 | 2020 | 88 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 2403 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 1362 | 0.080 |
Why?
|
| Survival Rate | 2 | 2018 | 12221 | 0.080 |
Why?
|
| Upper Extremity | 1 | 2009 | 87 | 0.080 |
Why?
|
| DNA, Ribosomal | 2 | 2021 | 103 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 2315 | 0.080 |
Why?
|
| Immunity, Cellular | 2 | 2020 | 419 | 0.080 |
Why?
|
| Hepatitis C | 1 | 2012 | 524 | 0.080 |
Why?
|
| T-Lymphocytes | 2 | 2016 | 3869 | 0.070 |
Why?
|
| Immunoglobulin G | 2 | 2021 | 1021 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 2027 | 0.070 |
Why?
|
| Prevalence | 2 | 2016 | 3260 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 1360 | 0.070 |
Why?
|
| DNA, Bacterial | 2 | 2021 | 558 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 5687 | 0.070 |
Why?
|
| Allografts | 2 | 2019 | 650 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2009 | 627 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 3976 | 0.060 |
Why?
|
| Betacoronavirus | 2 | 2020 | 527 | 0.060 |
Why?
|
| Risk | 1 | 2009 | 1972 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 4314 | 0.060 |
Why?
|
| Hepatitis B Antibodies | 2 | 2014 | 58 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2019 | 1144 | 0.060 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 140 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2021 | 6869 | 0.050 |
Why?
|
| Prognosis | 2 | 2020 | 21713 | 0.050 |
Why?
|
| Censuses | 1 | 2022 | 19 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4557 | 0.050 |
Why?
|
| HIV Infections | 1 | 2014 | 2134 | 0.050 |
Why?
|
| Spatial Analysis | 1 | 2022 | 35 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1945 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 543 | 0.050 |
Why?
|
| Health Facilities | 1 | 2022 | 79 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 4053 | 0.050 |
Why?
|
| Transplantation, Homologous | 2 | 2018 | 2843 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2022 | 4320 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 237 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 76 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2021 | 2483 | 0.050 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2020 | 51 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2021 | 383 | 0.050 |
Why?
|
| Antibody Affinity | 1 | 2020 | 61 | 0.050 |
Why?
|
| Azithromycin | 1 | 2020 | 78 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 10331 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 240 | 0.040 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2019 | 38 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2012 | 8223 | 0.040 |
Why?
|
| Public Health | 1 | 2021 | 299 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 826 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 577 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 254 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2023 | 787 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 1533 | 0.040 |
Why?
|
| Foscarnet | 1 | 2016 | 17 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 717 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 524 | 0.040 |
Why?
|
| Mutation | 1 | 2016 | 15179 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 629 | 0.040 |
Why?
|
| Lymphopenia | 1 | 2018 | 199 | 0.040 |
Why?
|
| Ganciclovir | 1 | 2016 | 174 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2016 | 73 | 0.030 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2016 | 129 | 0.030 |
Why?
|
| Biomarkers | 2 | 2019 | 5047 | 0.030 |
Why?
|
| Herpes Simplex | 1 | 2016 | 95 | 0.030 |
Why?
|
| Time Factors | 2 | 2020 | 12926 | 0.030 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2016 | 182 | 0.030 |
Why?
|
| Universal Precautions | 1 | 2014 | 5 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2018 | 474 | 0.030 |
Why?
|
| Metformin | 1 | 2019 | 378 | 0.030 |
Why?
|
| Betaproteobacteria | 1 | 2014 | 6 | 0.030 |
Why?
|
| Burkholderia cepacia | 1 | 2014 | 7 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 2139 | 0.030 |
Why?
|
| Interferons | 1 | 2016 | 291 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2018 | 1258 | 0.030 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2014 | 128 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 343 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2014 | 55 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1274 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2014 | 73 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2016 | 333 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2019 | 962 | 0.030 |
Why?
|
| Cancer Survivors | 1 | 2021 | 650 | 0.030 |
Why?
|
| Neutropenia | 1 | 2018 | 968 | 0.030 |
Why?
|
| Infection Control | 1 | 2016 | 270 | 0.030 |
Why?
|
| Registries | 1 | 2022 | 2170 | 0.030 |
Why?
|
| Interleukins | 1 | 2016 | 325 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2016 | 435 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2015 | 430 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2019 | 878 | 0.030 |
Why?
|
| Patient Selection | 1 | 2021 | 2055 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 298 | 0.030 |
Why?
|
| China | 1 | 2014 | 606 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 2218 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2014 | 844 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 620 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2016 | 769 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 1053 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 3981 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 544 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5377 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 2437 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 4298 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2023 | 3341 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 1555 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 3890 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 4233 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2016 | 2054 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 918 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2016 | 1589 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2016 | 2086 | 0.020 |
Why?
|
| Leukemia | 1 | 2016 | 1635 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 6089 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 6682 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 2588 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 14889 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 4367 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 14551 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 3251 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 8873 | 0.010 |
Why?
|